Bureau for Cancer Research
We turn our ideas into research protocols that can change reality and expand understanding of cancer pathogenesis and treatment.
What is
our power
our power
Lets talk ●
2007—2025
Thrue interaction with international experts and based on internal experience, the Bureau organizes and conducts basic and clinical research in oncology.
Research &
Power
The Bureau for Cancer Research is an independent, non-government, non-profit, cooperative cancer research group established to initiate and conduct preclinical, translational, and clinical studies in oncology.
About
Our mission
Our main aim is to improve overall survival by exploring new methods of diagnosis and treatment.
The Bureau for Cancer Research is founded as a legacy of Kidney Cancer Research Bureau, which was founded in 2007.
23
38
Clinical trials were conducted
Drug was developed. It is a humanized monoclonal anti-FGFR1 antibody.
Scientific articles have been published in peer-reviewed journals with 2000+ citations.
Facts
1
26
Preclinical and translational studies have been carried out
Benefits
Advantages
In-house projects
International Collaboration
Multidisciplinary team
Education
All projects are based on our own ideas, which are then turned into research protocols. Each concept is discussed and approved by a group of experts. Instead of relying on a subcontractor or another organization, the Bureau initially uses its own time, staff and resources to complete the task.
The Bureau conducts joint studies with colleagues in the USA, Germany, France, Italy, Russia, Kazakhstan, Azerbaijan, Georgia and China.
The team of experts depends on the type of study. We attract the best experts from various fields of cancer treatment to participate in research. Our team includes medical oncologists, radiation oncologists, surgeons, biostatisticians, pathologists, specialists in molecular biology and others.
One of the objectives of the Bureau is educational activities. We implement educational projects in various countries. Meetings in 2023:
- Asian American Genitourinary Cancer Symposium under the auspices of the American Society of Clinical Oncology (ASCO-recommended meeting)
- InterAsian Cancer Seminar "Current clinical challenges in oncology" (ESO-recommended meeting)
We would love to hear from you. Let’s work — together
in
touch
get
Lets talk ●
Contact us
Highlights from 2020 to 2025: selected projects
Projects
Latest projects are presented here (2020-2025)
2025 -
VOLGA 2: A RANDOMIZED PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF SBRT COMBINED WITH CONTINUED AVELUMAB MAINTENANCE THERAPY VERSUS SWITCHING TO SECOND-LINE TREATMENT IN PATIENTS WITH OLIGOPROGRESSION OF METASTATIC UROTHELIAL CANCER DURING AVELUMAB MAINTENANCE THERAPY
Ongoing
2024 -
CARMENITA: A RANDOMIZED PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF CYTOREDUCTIVE NEPHRECTOMY FOLLOWED BY IMMUNOTARGETED THERAPY OR ONLY IMMUNOTARGETED THERAPY IN PATIENTS WITH METASTATIC CLEAR-CELL RENAL CELL CARCINOMA AND PRIMARY TUMOR IN SITU
Seeking funding
A PHASE 1/2 STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF MELDONIUM IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND TREATMENT-ASSOCIATED FATIGUE.
Ongoing
Ongoing
OVERCOMING RESISTANCE TO IMMUNOTHERAPY WITH FGFR INHIBITION IN LUNG CANCER MODELS: PRECLINICAL STUDIES (OM-RCA-01 antibody)
Completed
Completed
A PROSPECTIVE PHASE 2 NIVOFGFR2 STUDY: NIVOLUMAB COMBINED WITH CHEMOTHERAPY IN FGFR2 AND PD-L1 CO-EXPRESSING METASTATIC GASTRIC CANCER
Completed
Completed
THE AMBISPECTIVE RAVE-RENAL STUDY: REAL-WORLD EFFICACY AND SAFETY OF AVELUMAB PLUS AXITINIB IN METASTATIC RENAL CELL CARCINOMA
Completed
Completed
THE AMBISPECTIVE RAVE-BLADDER STUDY: MAINTENANCE THERAPY WITH AVELUMAB FOR PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA
Completed
Completed
OSURK REGISTRY STUDY: FIVE-YEAR OVERALL SURVIVAL OF PATIENTS WITH ADVANCED BLADDER CANCER IN KAZAKHSTAN
Completed
Completed
PEMBROLIZUMAB AND LENVATINIB IN FIRST-LINE TREATMENT OF METASTATIC PAPILLARY RENAL CELL CARCINOMA: A PHASE 2 PILOT STUDY
Completed
Completed
2020 - 2024
NIVOLUMAB PLUS IPILIMUMAB IN T1AN0M0 RENAL CELL CARCINOMA PATIENTS INELIGIBLE FOR SURGERY AND ABLATION: A PHASE 2 STUDY
Completed
Completed
A PHASE 2 RANDOMIZED STUDY FARETES: TESTOSTERONE FOR MANAGING TREATMENT-RELATED FATIGUE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Completed
Completed
INTRAPLEURAL NIVOLUMAB IN CANCER PATIENTS WITH PLEURAL EFFUSION: A PILOT CLINICAL STUDY
Terminated early
Terminated early
THE RENSUR3 REGISTRY STUDY: OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN RUSSIA, KAZAKHSTAN, AND BELARUS
Completed
Completed
A MATCHED COHORT STUDY: NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND CHRONIC HEPATITIS C VIRUS INFECTION
Completed
Completed
EXPRESSION OF RECEPTOR TYROSINE KINASES ON PERIPHERAL BLOOD MONONUCLEAR CELLS AND TUMOR-INFILTRATING LYMPHOCYTES IN PATIENTS WITH RENAL CELL CARCINOMA AND HEALTHY DONORS
Completed
A PROSPECTIVE MULTICENTRE STUDY (VOLGA): STEREOTACTIC BODY RADIATION THERAPY IN COMBINATION WITH SYSTEMIC THERAPY FOR METASTATIC RENAL CELL CARCINOMA
Completed
Completed
hi
oh
Team
CEO
Advisory Board Member
Advisory Board Member
Advisory Board Member
How it works
Just
do it
01 —
The first step
The first step
The main step is to come up with a brilliant idea and evaluate its value.
06 —
The last move
The last move
Co-authors present data at conferences and publish articles in journals.
02 —
Make it possible
Make it possible
The second step of a long journey is to determine the correct sequence of actions and develop strategic plan. At this step, we are looking for funding and like-minded collaborators around the world.
04 —
Don't stop
Don't stop
At this stage, study is underway, and we cannot stop until we get the results.
05 —
Now or never
Now or never
Conclusions based on the results of the study are made by the co-authors and members of the Advisory board.
03 —
Big inner work
Big inner work
Development of the protocol, organization of the study and preparation for launch.
Support
The Importance of Cancer Research
National Cancer Institute
Recent decades have seen tremendous progress against cancer, as evidenced by a 26 percent decline in cancer-related deaths in the U.S. between 2000 and 2019.
SEER Database
Philip D. Greenberg
"The confluence of advances in many intersecting biologic and technologic fields offers great promise, and it will be a challenge to help harness these advances, enhance access by members of the research community to the new technologies, and translate this progress for the benefit of patients".
AACR President-Elect (2022-2023)
Julie R. Gralow
ASCO chief medical officer
"Cancer research needs to be inclusive in order for it to be most effective. We need to ensure that all types of diversity are represented in our cancer research community, our patient population that’s enrolling in clinical trials, and our workforce pipeline of future researchers and physicians. Learning from all patients, providers, and researchers gives us our best chance to provide high-quality care to all patients and build the biggest knowledge base".
Cancer Research
Contacts
+1 917-891-4943
Since 2007
New York, NY 10032
526 W. 158th street
526 W. 158th street
Instagram
Twitter
YouTube
bucare@bucare.org